Logo
Phone Icon
1-855-4-MEDINFO (855-463-3463)

1-855-4-MEDINFO (855-463-3463)

[email protected]
Back

Povorcitinib

Povorcitinib is an investigational, oral JAK1 inhibitor.1

Recruiting & Ongoing Clinical Studies

Condition
Study Title
Phase
Resources & Links
Vitiligo
STOP-V1: A Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Patients With Nonsegmental Vitiligo
3
NCT06113445
Vitiligo
STOP-V2: A Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Patients With Nonsegmental Vitiligo
3
NCT06113471
Hidradenitis suppurativa
STOP-HS1: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Povorcitinib in Patients With Moderate to Severe Hidradenitis Suppurativa
3
NCT05620823 Watch Video
Hidradenitis suppurativa
STOP-HS2: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Povorcitinib in Patients With Moderate to Severe Hidradenitis Suppurativa
3
NCT05620836 Watch Video
Hidradenitis suppurativa
STOP-HS LTE: A Randomized, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Patients With Moderate to Severe Hidradenitis Suppurativa
3
NCT06212999 Watch Video
Hidradenitis suppurativa
An Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Povorcitinib in Adolescents With Moderate to Severe Hidradenitis Suppurativa
2
NCT07213973 View Resource
Prurigo nodularis
STOP-PN1: A Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Patients With Prurigo Nodularis
3
NCT06516952 View Resource
Prurigo nodularis
STOP-PN2: A Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Patients With Prurigo Nodularis
3
NCT06516965 View Resource
Asthma
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Patients With Inadequately Controlled Moderate to Severe Asthma
2
NCT05851443 View Resource
Hidradenitis suppurativa Vitiligo Prurigo nodularis
STOP-LTR: A Phase 3b, Multicenter, Rollover Study for Patients Previously Enrolled in Clinical Trials of Povorcitinib
3
NCT06855498

The Role of JAK1 Inhibition in Hidradenitis Suppurativa

Povorcitinib MOA Video

Janus kinases (JAKs) are intracellular signaling enzymes that act downstream of key proinflammatory cytokines to mediate normal immune function and modulate inflammation.2

The JAK family consists of JAK1, JAK2, JAK3, and TYK2, which activate signal transducer and activator of transcription (STAT) proteins that promote gene transcription.2

JAK/STAT signaling is involved in various inflammatory and autoimmune skin diseases.2,3

References: 1. Fay B, et al. Ann Rheum Dis. 2019;78:221-222. 2. Howell MD, et al. Front Immunol. 2019;10:2342. 3. Szilveszter KP, et al. Front Immunol. 2019;10:1862.

Top